Effect of GLP-1 on Angiogenesis

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT02686177
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications associated with T2D. Few studies have properly addressed the role of GLP-1-based therapies in regulating vascular integrity and angiogenesis. The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2 and ANGLPT4 levels and endothelial circulating progenitor cells, angiogenesis biomarkers in type 2 diabetic patients.

Key Dates

Start date
May 18, 2016
Status verified
Jun 2021
Primary completion
Aug 8, 2017
Completion
May 28, 2021

Study Design

Enrollment
50 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1: Liraglutide
    Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
  • Active Comparator: 2: Add on oral antidiabetic medication
    Metformin or sulfonylurea depending on monotherapy

Primary Outcome Measure

Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group [ Time Frame: At 1 month ]

Related Studies